Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,428.38 3.53 0.02%
S&P 500 1,864.02 1.71 0.09%
NASDAQ 4,095.94 9.71 0.24%
Ticker Volume Price Price Delta
STOXX 50 3,151.54 12.28 0.39%
FTSE 100 6,622.26 38.09 0.58%
DAX 9,396.65 78.83 0.85%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

PositiveID Corporation Announces Teaming Agreement With SAIC to Pursue Defense Threat Reduction Agency Contracts



PositiveID Corporation Announces Teaming Agreement With SAIC to Pursue Defense
Threat Reduction Agency Contracts

Companies to Pursue Weapons of Mass Destruction - Defeat Technology, Arms
Control, and Nuclear Technology Electromagnetic Research and
Development/Survivability and Infrastructure Programs

DELRAY BEACH, Fla., Nov. 6, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation
("PositiveID") (OTCBB:PSID), an emerging growth company and developer of
airborne bio-threat detection systems for America's homeland defense industry
as well as advanced technologies for diabetes management and rapid medical
testing, today announced it has signed a Teaming Agreement ("Teaming
Agreement") with Science Applications International Corporation ("SAIC")
(NYSE:SAI) to pursue the Defense Threat Reduction Agency ("DTRA") Indefinite
Delivery/Indefinite Quantity ("IDIQ") Multiple Award Contracts supporting the
Weapons of Mass Destruction ("WMD") - Defeat Technology, Arms Control, and
Nuclear Technology Electromagnetic Research and Development/ Survivability and
Infrastructure programs.

The Teaming Agreement pairs SAIC's system engineering and integration
capabilities with PositiveID's bio-threat detection technologies. PositiveID
will offer both its Dragonfly™ Rapid MD-x Cartridge-based diagnostic system
("Dragonfly") as well as its M-BAND (Microfluidics-based Bioagent Networked
Detector) airborne bio-threat detector as part of the Teaming Agreement.

PositiveID's Dragonfly system is designed to deliver molecular diagnostic
results from a sample in less than 30 minutes, which would enable accurate
diagnostics leading to potential treatment scenarios at the point of care that
are not possible with existing systems. Dragonfly is being developed further
for a broad range of biological detection situations including
radiation-induced cell damage within the human body, strains of influenza and
other common pathogens and diseases such as E. coli, methicillin-resistant
staphylococcus aureus ("MRSA") and human papilloma virus ("HPV").

PositiveID's M-BAND, developed under contract for the Department of Homeland
Security Science and Technology Division, is a bioaerosol monitor with fully
integrated systems with sample collection, processing and detection modules
that continuously analyze air samples for the detection of bacteria, viruses,
and toxins with results in as little as two hours. Results from individual
M-BAND instruments are reported via a secure wireless network in real time to
give an accurate and up to date status for fielded instruments in the
aggregate.

William J. Caragol, Chairman and CEO of PositiveID, stated, "We are very
pleased to team with SAIC through this agreement, and demonstrate the value
and capabilities of our Dragonfly and M-BAND technologies."

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of airborne
bio-threat detection systems for America's homeland defense industry as well
as advanced technologies for diabetes management and rapid medical testing.
Its wholly-owned subsidiary, Microfluidic Systems, is focused on the
development of microfluidic systems for the automated preparation of and
performance of biological assays in order to detect biological threats at
high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit
http://www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the likelihood
that the companies will pursue the DTRA IDIQ Multiple Award Contracts
supporting the WMD - Defeat Technology, Arms Control, and Nuclear Technology
Electromagnetic Research and Development/ Survivability and Infrastructure
programs; the likelihood that PositiveID will offer both its Dragonfly as well
as its M-BAND airborne bio-threat detector as part of the Teaming Agreement;
the likelihood that PositiveID's Dragonfly is designed to deliver molecular
diagnostic results from a sample in less than 30 minutes, which would enable
accurate diagnostics leading to potential treatment scenarios at the point of
care that are not possible with existing systems; the likelihood that
Dragonfly is being developed further for a broad range of biological detection
situations including radiation-induced cell damage within the human body,
strains of influenza and other common pathogens and diseases such as E. coli,
MRSA and HPV; and all other statements in this press release other than
historical facts are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks and
uncertainties and are subject to change at any time, and PositiveID's actual
results could differ materially from expected results. These risks and
uncertainties include PositiveID's ability to successfully pursue the DTRA
IDIQ Multiple Award Contracts supporting the WMD - Defeat Technology, Arms
Control, and Nuclear Technology Electromagnetic Research and Development/
Survivability and Infrastructure programs; as well as certain other risks.
Additional information about these and other factors that could affect the
Company's business is set forth in the Company's various filings with the
Securities and Exchange Commission, including those set forth in the Company's
10-K filed on March 28, 2012, as amended on May 4, 2012, and 10-Qs filed on
August 20, 2012, as amended on September 12, 2012, May 14, 2012, and November
14, 2011, under the caption "Risk Factors." The Company undertakes no
obligation to update or release any revisions to these forward-looking
statements to reflect events or circumstances after the date of this statement
or to reflect the occurrence of unanticipated events, except as required by
law.

CONTACT: PositiveID Corporation
         Allison Tomek
         561-805-8000
         atomek@positiveidcorp.com

PositiveID Corporation Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement